Research
Hormonal
Tirzepatide (dual GIP/GLP-1 agonist) produces significantly greater weight loss and waist circumference reduction than semaglutide (selective GLP-1 agonist) in adults with obesity without diabetes.
If your primary goal is maximum weight loss and you do not have diabetes, tirzepatide (15mg weekly) is clinically superior to semaglutide (2.4mg weekly). While both are effective, tirzepatide yields significantly greater fat loss and waist reduction. Be aware that while tirzepatide may have better GI tolerability, it still carries class-specific risks.
StrongSupportsHIGH confidence
In this study, which enrolled 670 participants and included a 72-week follow-up, once-weekly tirzepatide 15 mg induced a mean body weight reduction of 20.2%, significantly greater than the 13.7% achieved with semaglutide 2.4 mg (P < 0.001)... Beyond weight loss, tirzepatide exerted a more favourable effect on waist circumference... (Table 1).
Why this rating
Based on a randomized, head-to-head clinical trial (SURMOUNT-5) with statistically significant results.
Source
Tirzepatide and semaglutide: different twins?
A. Cesaro et al. · European Heart Journal Supplements · 2026
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →